Chinese researchers have been granted access to British Grand Prix records of half a million, despite concerns from Western intelligence agencies about the authoritarian regime’s accumulation of health data, as revealed by the Guardian.
The records are set to be transferred to UK Biobank, a research hub housing detailed medical information from 500,000 volunteers. This extensive health data repository is made accessible to universities, scientific institutions, and private companies. Guardian analysis indicates that one of the five successful applications for access originates from China.
Health authorities had been evaluating the need for additional protection measures for patient records as they are integrated with genomes, tissue samples, and questionnaire responses at UK Biobank. Personal details such as date of birth are stripped from UK Biobank data before sharing, but experts warn that in some instances, individuals could still be identifiable.
Despite warnings from MI5 about Chinese entities accessing UK data under the direction of China’s intelligence agency, UK Biobank, which oversees health data, has recently given clearance for Chinese researchers to access GP records.
As UK Ministers cozy up to Beijing in pursuit of economic growth, the decision reflects a delicate balance to avoid antagonizing the influential superpower, which prioritizes biotechnology advancement. The UK-China relationship is already under strain due to issues like the ownership of a China-owned steel factory in Scunthorpe and new regulations on foreign interference.
A government spokesperson emphasized that security and privacy are paramount considerations when utilizing UK health data for disease understanding and scientific research. They reassured that health data is only shared with legitimate researchers.
The UK Biobank has been a major success in advancing global medical research, according to Chi Onwurah, a Labour MP heading the Congressional Science and Technology Committee. She stressed the need for a comprehensive government strategy to ensure data control and secure, responsible data sharing in the geopolitical landscape.
Approval of access to patient records
Out of 1,375 successful applications for UK Biobank data access, nearly 20% come from China, second only to the US. Chinese researchers have leveraged UK Biobank data for research on topics like air pollution and dementia prediction.
In recent years, the US government has imposed restrictions on BGI subsidiaries due to concerns about their collection and analysis of genetic data potentially aiding Chinese military programs. Nevertheless, UK Biobank approved a research project with a BGI unit, emphasizing the need for strict compliance with UK data laws.
The UK Biobank representative dismissed claims of genetic surveillance or unethical practices by BGI, stating that the focus is on civilian and scientific research. The UK Biobank continues to engage with MI5 and other state agencies to oversee data use, including collaborations with Chinese entities.
Despite some opposition, patient records are being transferred to UK Biobanks and other research hubs as part of a directive from the Health Secretary. Access to these records is strictly regulated by NHS England based on security and data protection considerations.
NHS England requires overseas data recipients to be authorized for access to personal data in compliance with UK data laws. Regular audits ensure that data sharing processes meet security standards. Chinese researchers can now apply for access to GP records through the approved platform.
China is “developing the world’s largest biodatabase.”
Data repositories like UK Biobank play a crucial role in global research efforts, with some experts cautioning about China’s intent to leverage genomic and health data for biotech advancement. Intelligence sources suggest that health data could be exploited for espionage if anonymization is breached.
MI5 raised concerns about China’s National Intelligence Act and its implications for personal data controllers interacting with Chinese entities. China’s ambition to develop a vast biodatabase has drawn scrutiny from intelligence officials worldwide.
Privacy advocates have questioned the transfer of UK health data to China, urging vigilance against potential misuse in “hostile states.” UK Biobank has revamped its data sharing practices to enhance security and ensure that patient data is safeguarded.
Despite the concerns, UK Biobank CEO Professor Rory Collins underscores the importance of explicit consent from volunteers for studying health data, particularly GP records.
Source: www.theguardian.com
